Want to see HK:9966 full AI Analyst Report?
Alphamab Oncology (9966) Stock Statistics & Valuation Metrics
Total Valuation
Alphamab Oncology has a market cap or net worth of HKD 6.06B. The enterprise value is HKD 5.37B.
- Market Cap
- HKD 6.06B
- Enterprise Value
- HKD 5.37B
Share Statistics
Alphamab Oncology has 974,381,700 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 974,381,700
- Owned by Insiders
- ―
- Owned by Institutions
- 4.30%
Financial Efficiency
Alphamab Oncology’s return on equity (ROE) is -0.06 and return on invested capital (ROIC) is -8.06%.
- Return on Equity (ROE)
- -0.06
- Return on Assets (ROA)
- -0.05
- Return on Invested Capital (ROIC)
- -8.06%
- Return on Capital Employed (ROCE)
- -0.08
- Revenue Per Employee
- 1.07M
- Profits Per Employee
- -215.51K
- Employee Count
- 515
- Asset Turnover
- 0.26
- Inventory Turnover
- 1.16
Valuation Ratios
The current PE Ratio of Alphamab Oncology is -30.62. Alphamab Oncology’s PEG ratio is 0.25.
- PE Ratio
- -30.62
- PS Ratio
- 9.91
- PB Ratio
- 3.04
- Price to FCF
- -29.69
- Price to Operating Cash Flow
- -32.64
- PEG Ratio
- 0.25
Income Statement
In the last 12 months, Alphamab Oncology had revenue of 551.58M and earned -110.99M in profits. Earnings per share was -0.12.
- Revenue
- 551.58M
- Gross Profit
- 426.67M
- Operating Income
- -149.32M
- Pretax Income
- -110.99M
- Net Income
- -110.99M
- EBITDA
- -84.64M
- Earnings Per Share (EPS)
- -0.12
Cash Flow
In the last 12 months, operating cash flow was -155.89M and capital expenditures -15.80M, giving a free cash flow of -171.69M billion.
- Operating Cash Flow
- -155.89M
- Free Cash Flow
- -171.69M
- Free Cash Flow per Share
- -0.18
Dividends & Yields
Alphamab Oncology pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -3.37%
- Earnings Yield
- -3.42%
Stock Price Statistics
- Beta
- 0.81
- 52-Week Price Change
- -45.77%
- 50-Day Moving Average
- 7.85
- 200-Day Moving Average
- 8.39
- Relative Strength Index (RSI)
- 34.92
- Average Volume (3m)
- 1.24M
Important Dates
Alphamab Oncology upcoming earnings date is Mar 30, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Aug 27, 2026
- Next Earnings Date
- Mar 30, 2027
- Ex-Dividend Date
- ―
Financial Position
Alphamab Oncology as a current ratio of 5.67, with Debt / Equity ratio of 7.19%
- Current Ratio
- 5.67
- Quick Ratio
- 5.29
- Debt to Market Cap
- 0.01
- Net Debt to EBITDA
- 1.60
- Interest Coverage Ratio
- -20.58
Taxes
In the past 12 months, Alphamab Oncology has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Alphamab Oncology EV to EBITDA ratio is -38.12, with an EV/FCF ratio of -29.03.
- EV to Sales
- 9.69
- EV to EBITDA
- -38.12
- EV to Free Cash Flow
- -29.03
- EV to Operating Cash Flow
- -31.97
Balance Sheet
Alphamab Oncology has HKD 1.43B in cash and marketable securities with HKD 268.36M in debt, giving a net cash position of HKD 1.16B billion.
- Cash & Marketable Securities
- HKD 1.43B
- Total Debt
- HKD 268.36M
- Net Cash
- HKD 1.16B
- Net Cash Per Share
- HKD 1.19
- Tangible Book Value Per Share
- HKD 1.73
Margins
Gross margin is 76.09%, with operating margin of -38.04%, and net profit margin of -33.79%.
- Gross Margin
- 76.09%
- Operating Margin
- -38.04%
- Pretax Margin
- -33.79%
- Net Profit Margin
- -33.79%
- EBITDA Margin
- -25.42%
- EBIT Margin
- -38.04%
Analyst Forecast
The average price target for Alphamab Oncology is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -31.77%
- EPS Growth Forecast
- -177.01%
Scores
- Smart Score
- 7
- AI Score
- 47